公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
2016 | Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: Post hoc analyses of the randomized LUX-Lung 3 and 6 trials | CHIH-HSIN YANG ; Sequist L.V; Zhou C; Schuler M; Geater S.L; Mok T; Hu C.-P; Yamamoto N; Feng J; O'Byrne K; Lu S; Hirsh V; Huang Y; Sebastian M; Okamoto I; Dickgreber N; Shah R; Märten A; Massey D; Wind S; Wu Y.-L. | Annals of Oncology | 152 | 142 | |
2022 | The Effect of Intrathoracic Lesion Location on Initial Tyrosine Kinase Inhibitor Response in Advanced Oncogene-Addicted Non-Small Cell Lung Cancer: A Comparison Between RECIST 1.1 and a Novel Method of Response Assessment (MAX) | Bang, Tami J; Hu, Junxiao; Patil, Tejas; Barón, Anna E; Gao, Dexiang; CHIH-HSIN YANG ; HUNG-YANG KUO ; HSIN-CHIEH HUANG ; Sachs, Peter B; Camidge, D Ross | Clinical lung cancer | 0 | 0 | |
2018 | The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib | Vishwanathan K; Dickinson P.A; So K; Thomas K; Chen Y.-M; De Castro Carpeño J; Dingemans A.-M.C; Kim H.R; Kim J.-H; Krebs M.G; Chih-Hsin CHIH-HSIN YANG ; Bui K; Weilert D; Harvey R.D. | British Journal of Clinical Pharmacology | 45 | 42 | |
2020 | The effectiveness of afatinib in patients with lung adenocarcinoma harboring complex epidermal growth factor receptor mutation | SHANG-GIN WU ; CHONG-JEN YU ; CHIH-HSIN YANG ; JIN-YUAN SHIH | Therapeutic Advances in Medical Oncology | 16 | 15 | |
2011 | Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer | Wu J.-Y.; CHONG-JEN YU ; YEUN-CHUNG CHANG ; CHIH-HSIN YANG ; JIN-YUAN SHIH ; PAN-CHYR YANG | Clinical Cancer Research | 412 | 364 | |
2017 | Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC | Wu Y.-L; Saijo N; Thongprasert S; CHIH-HSIN YANG ; Han B; Margono B; Chewaskulyong B; Sunpaweravong P; Ohe Y; Ichinose Y; Yang J.-J; Mok T.S.K; Young H; Haddad V; Rukazenkov Y; Fukuoka M. | Lung Cancer | 48 | 38 | |
2022 | Efficacy and Safety of Brigatinib Compared With Crizotinib in Asian vs. Non-Asian Patients With Locally Advanced or Metastatic ALK-Inhibitor-Naive ALK+ Non-Small Cell Lung Cancer: Final Results From the Phase III ALTA-1L Study | Ahn, Myung J; Kim, Hye R; CHIH-HSIN YANG ; Han, Ji-Yu; Li, Jacky Yu-Chung; Hochmair, Maximilian J; Chang, Gee-Chen; Delmonte, Angelo; Lee, Ki H; Campelo, Rosario G; Gridelli, Cesare; Spira, Alexander I; Califano, Raffaele; Griesinger, Frank; Ghosh, Sharmistha; Felip, Enriqueta; Kim, Dong-Wan; Liu, Yuyin; Zhang, Pingkuan; Popat, Sanjay; Camidge, D Ross | Clinical lung cancer | 5 | 4 | |
2010 | Efficacy and safety of cisplatin/pemetrexed versus cisplatin/gemcitabine as first-line treatment in east asian patients with advanced non-small cell lung cancer: Results of an exploratory subgroup analysis of a phase III trial | CHIH-HSIN YANG ; Simms L; Park K; Lee J.S; Scagliotti G; Orlando M. | Journal of Thoracic Oncology | 50 | 43 | |
2022 | Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small Cell Lung Cancer | Jänne P.A.; Baik C.; Su W.-C.; Johnson M.L.; Hayashi H.; Nishio M.; Kim D.-W.; Koczywas M.; Gold K.A.; Steuer C.E.; Murakami H.; CHIH-HSIN YANG ; Kim S.-W.; Vigliotti M.; Shi R.; Qi Z.; Qiu Y.; Zhao L.; Sternberg D.; Yu C.; Yu H.A. | Cancer discovery | 118 | 85 | |
2021 | Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With EGFR-Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized Study | CHIH-HSIN YANG ; Reckamp K.L.; Kim Y.-C.; Novello S.; Smit E.F.; Lee J.-S.; Su W.-C.; Akerley W.L.; Blakely C.M.; Groen H.J.M.; Bazhenova L.; Carcereny Costa E.; Chiari R.; Hsia T.-C.; Golsorkhi T.; Despain D.; Shih D.; Popat S.; Wakelee H. | JTO Clinical and Research Reports | 10 | 0 | |
2021 | Efficacy and Safety of S-1 Compared With Docetaxel in Elderly Patients With Advanced NSCLC Previously Treated With Platinum-Based Chemotherapy: A Subgroup Analysis of the EAST-LC Trial | CHIH-HSIN YANG ; Mok T.S.K.; Lu S.; Nakagawa K.; Yamamoto N.; Shi Y.-K.; Zhang L.; Soo R.A.; Morita S.; Tamura T. | JTO Clinical and Research Reports | 0 | 0 | |
2017 | Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non–small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria | Gandhi L; Ignatius Ou S.-H; Shaw A.T; Barlesi F; Dingemans A.-M.C; Kim D.-W; Camidge D.R; Hughes B.G.M; CHIH-HSIN YANG ; de Castro J; Crino L; Léna H; Do P; Golding S; Bordogna W; Zeaiter A; Kotb A; Gadgeel S. | European Journal of Cancer | 27 | 24 | |
2022 | Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational Trial | Lu S.; Wang Q.; Zhang G.; Dong X.; Yang C.-T.; Song Y.; Chang G.-C.; Lu Y.; Pan H.; Chiu C.-H.; Wang Z.; Feng J.; Zhou J.; Xu X.; Guo R.; Chen J.; Yang H.; Chen Y.; Yu Z.; Shiah H.-S.; Wang C.-C.; Yang N.; Fang J.; Wang P.; Wang K.; Hu Y.; He J.; Wang Z.; Shi J.; Chen S.; Wu Q.; Sun C.; Li C.; Wei H.; Cheng Y.; Su W.-C.; Hsia T.-C.; Cui J.; Sun Y.; Ou S.-H.I.; Zhu V.W.; CHIH-HSIN YANG | Journal of Thoracic Oncology | 72 | 51 | |
2016 | Efficacy of pemetrexed-based chemotherapy in patients with ROS1 fusion-positive lung adenocarcinoma compared with in patients harboring other driver mutations in East Asian populations | YEN-FU CHEN ; MIN-SHU HSIEH ; SHANG-GIN WU ; YIH-LEONG CHANG ; CHONG-JEN YU ; CHIH-HSIN YANG ; PAN-CHYR YANG ; JIN-YUAN SHIH | Journal of Thoracic Oncology | 63 | 51 | |
2012 | Effusion immunocytochemistry as an alternative approach for the selection of first-line targeted therapy in advanced lung adenocarcinoma | TZU-HSIU TSAI ; SHANG-GIN WU ; YIH-LEONG CHANG ; CHEN-TU WU ; Tsai M.-F.; Wei P.-F.; CHIH-HSIN YANG ; CHONG-JEN YU ; PAN-CHYR YANG ; JIN-YUAN SHIH | Journal of Thoracic Oncology | 22 | 26 | |
2013 | EGFR inhibitors as the first-line systemic treatment for advanced non-small-cell lung cancer | HSIANG-FONG KAO ; CHIA-CHI LIN ; CHIH-HSIN YANG | Future Oncology | 7 | 6 | |
2009 | EGFR intron 1 dinucleotide repeat polymorphism is associated with the occurrence of skin rash with gefitinib treatment | Huang C.-L.; CHIH-HSIN YANG ; KUN-HUEI YEH ; Hu F.-C.; KUAN-YU CHEN ; JIN-YUAN SHIH ; ZHONG-ZHE LIN ; CHONG-JEN YU ; ANN-LII CHENG ; PAN-CHYR YANG | Lung Cancer | 43 | 36 | |
2017 | EGFR Mutation Analysis for Prospective Patient Selection in Two Phase II Registration Studies of Osimertinib | Jenkins S; Chih-Hsin CHIH-HSIN YANG ; Jänne P.A; Thress K.S; Yu K; Hodge R; Weston S; Dearden S; Patel S; Cantarini M; Shepherd F.A. | Journal of Thoracic Oncology | 48 | 49 | |
2017 | EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: Analysis of LUX-Lung 3 and 6 | Wu Y.-L; Sequist L.V; Hu C.-P; Feng J; Lu S; Huang Y; Li W; Hou M; Schuler M; Mok T; Yamamoto N; O'Byrne K; Hirsh V; Gibson N; Massey D; Kim M; CHIH-HSIN YANG | British Journal of Cancer | 70 | 60 | |
2021 | EGFR tyrosine kinase inhibitors for EGFR mutation-positive non-small-cell lung cancer: Outcomes in Asian populations | Kim E.S.; Melosky B.; Park K.; Yamamoto N.; CHIH-HSIN YANG | Future Oncology | 13 | 12 | |